Perspective Therapeutics (CATX) Stock Price, News & Analysis

Company Overview

Perspective Therapeutics, Inc. is a clinical-stage biotechnology company developing precision-targeted radiopharmaceuticals for the treatment of cancer. The company focuses on therapies that combine tumor-targeting molecules with radioactive isotopes designed to deliver radiation directly to malignant cells while limiting exposure to surrounding healthy tissue.

Perspective Therapeutics’ proprietary VMT platform is intended to support the development of both therapeutic and diagnostic radiopharmaceuticals. Its pipeline has included VMT01, a targeted alpha therapy being studied for patients with metastatic melanoma, and VMT-α-NET, a program designed to target somatostatin receptor-positive neuroendocrine tumors. These programs are being evaluated in clinical studies to assess their safety, targeting capabilities and potential therapeutic benefits.

The company is headquartered in Seattle, Washington, and is developing the infrastructure and manufacturing capabilities needed to support radiopharmaceutical production and clinical development. Perspective Therapeutics serves the oncology market through its research and development activities, with a focus on cancers that can be identified through molecular targets and treated using targeted alpha-particle therapy.

Key Stats

• Today's Range: $2.46 to $2.53
• 50-Day Range: $2.50 to $3.48
• 52-Week Range: $1.96 to $6.16
• Volume: 178,941 shs
• Average Volume: 2.24 million shs
• Market Capitalization: $287.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.50
• Consensus Rating: Buy

Perspective Therapeutics Stock Analysis - MarketRank™

Perspective Therapeutics scored higher than 47% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Perspective Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 9 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Perspective Therapeutics has a consensus price target of $11.50, representing about 356.3% upside from its current price of $2.52.

Amount of Analyst Coverage

Perspective Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Perspective Therapeutics are expected to decrease in the coming year, from ($0.98) to ($1.08) per share.

Price to Book Value per Share Ratio

Perspective Therapeutics has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.59% of the float of Perspective Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Perspective Therapeutics has a short interest ratio ("days to cover") of 16.85, which indicates bearish sentiment.

Change versus previous month

Short interest in Perspective Therapeutics has recently decreased by 2.34%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Perspective Therapeutics does not currently pay a dividend.

Dividend Growth

Perspective Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 4 people have searched for CATX on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.

MarketBeat Follows

7 people have added Perspective Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Perspective Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.99% of the stock of Perspective Therapeutics is held by insiders.

Percentage Held by Institutions

54.66% of the stock of Perspective Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 9/28/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:CATX
• Previous Symbol: NYSE:CATX
• CIK: 728387
• Web: www.perspectivetherapeutics.com
• Phone: 206-676-0900
• Fax: 509-267-3670
• Employees: 166
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Perspective Therapeutics: $11.50
• High Price Target: $14.00
• Low Price Target: $5.00
• Potential Upside/Downside: +345.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$103.12 million
• Net Margins: -28,467.97%
• Pretax Margin: -28,710.03%
• Return on Equity: -41.92%
• Return on Assets: -34.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.61
• Quick Ratio: 6.61

Sales & Book Value

• Annual Sales: $880 thousand
• Price / Sales: 334.67
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.79 per share
• Price / Book: 0.92

Miscellaneous

• Outstanding Shares: 114,150,000
• Free Float: 110,739,000
• Market Cap: $294.51 million
• Optionable: Optionable
• Beta: 1.80